Covid-19 roundup: Atea Phar­ma­ceu­ti­cals launch­es an­tivi­ral in­to PhI­II tri­al; Cell­tri­on's an­ti­body shows promise against vari­ant

About a year af­ter jump­ing in­to the Covid-19 fight with its lead an­tivi­ral, Atea Phar­ma­ceu­ti­cals has launched a Phase III tri­al in mild to mod­er­ate pa­tients who are not hos­pi­tal­ized.

The drug (and com­pa­ny) come from Jean-Pierre Som­ma­dos­si, the founder of Idenix and a co-founder of Phar­mas­set. The com­pa­ny de­cid­ed to di­vert all their at­ten­tion to Covid-19 last Feb­ru­ary, then pulled in $215 mil­lion to launch a cross-coun­try Phase II tri­al in May.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER